Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.

Thyroid : official journal of the American Thyroid Association - 1 Oct 2013

Russo Marika A, Kang Kristy S, Di Cristofano Antonio

Abstract excerpt

BACKGROUND: Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are the most aggressive forms of thyroid cancer. Despite their low incidence, they account for a disproportionate number of thyroid cancer-related deaths because of their resistance to most therapeutic approaches. We have generated mouse models that develop ATC ([Pten, p53](thyr-/-) mice) and follicular thyroid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Dedifferentiation
Share to Inhibitory Concentration 50

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, 129 Strain

Share to Neoplasm Transplantation

Share to Polo-Like Kinase 1

Share to Random Allocation

Share to Thiophenes

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 23509868
DOI: 10.1089/thy.2013.0037
PMCID: PMC3783934

Genes

PLK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.PMID 23509868Read ↗

dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastropheSemantic proximity Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologySemantic proximity Read ↗

A review of Plks: Thinking outside the (polo) boxSemantic proximity Read ↗

The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?Semantic proximity Read ↗

Faulty Metabolism: A Potential Instigator of an Aggressive Phenotype in Cdk5-dependent Medullary Thyroid CarcinomaSemantic proximity Read ↗

Plk1 Inhibition Causes Post-Mitotic DNA Damage and Senescence in a Range of Human Tumor Cell LinesSemantic proximity Read ↗

Dual targeting of PDPK1 and BRAF V600E is synthetically lethalSemantic proximity Read ↗

The Oncogenic Functions of MASTL KinaseSemantic proximity Read ↗

Present and Future Perspective on PLK1 Inhibition in Cancer TreatmentSemantic proximity Read ↗

Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancersSemantic proximity Read ↗

Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.